塞力医疗(603716) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 359,934,927.53, a growth of 38.41% year-on-year[6] - Net profit attributable to shareholders of the listed company was CNY 22,021,805.97, reflecting a 16.93% increase from the same period last year[6] - Basic earnings per share rose by 22.22% to CNY 0.11 compared to CNY 0.09 in the previous year[6] - The diluted earnings per share also increased by 22.22% to CNY 0.11[6] - Net profit for Q1 2019 reached ¥24,969,040.31, representing a 2.7% increase compared to ¥24,309,667.35 in Q1 2018[28] - Operating profit for Q1 2019 was ¥34,188,842.52, slightly up from ¥33,080,345.72 in Q1 2018[27] - The total profit for Q1 2019 was ¥33,247,525.35, a 3.1% increase from ¥32,256,003.25 in Q1 2018[28] Assets and Liabilities - Total assets increased by 8% to CNY 2,797,259,704.4 compared to the end of the previous year[6] - Total liabilities rose to CNY 1,136,352,028.00 from CNY 957,207,144.44, indicating an increase of about 18.7%[20] - Current liabilities rose to CNY 1,108,661,306.50, up from CNY 934,316,708.43, indicating an increase of about 18.7%[20] - The company’s long-term borrowings increased by 50.0% to RMB 14,137,200.00, reflecting financing for business expansion[14] - Accounts receivable increased to RMB 1,006,877,099.85 from RMB 867,416,693.41, indicating growth in sales and customer demand[18] - Inventory increased to CNY 211,582,408.41 from CNY 194,862,614.68, marking a rise of about 8.5%[23] - The company reported a total current asset of CNY 1,800,587,808.04, up from CNY 1,583,239,535.13, indicating an increase of about 13.8%[23] Cash Flow - The net cash flow from operating activities was CNY -87,951,292.41, worsening from CNY -62,453,577.98 in the previous year[6] - The company's cash inflow from operating activities for Q1 2019 was CNY 392,721,815.22, compared to CNY 212,914,465.88 in Q1 2018, representing an increase of approximately 84.5%[34] - The total cash outflow for operating activities was CNY 480,673,107.63 in Q1 2019, compared to CNY 275,368,043.86 in Q1 2018, representing an increase of approximately 74.5%[34] - The net cash inflow from financing activities was CNY 133,697,769.68 in Q1 2019, significantly higher than CNY 57,447,977.26 in Q1 2018, reflecting an increase of approximately 132.5%[35] - The net cash flow from investing activities was CNY -38,936,540.44 in Q1 2019, compared to CNY -66,394,474.80 in Q1 2018, showing an improvement of approximately 41.5%[35] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,264[10] - The largest shareholder, Tianjin Ruimei Scientific Instrument Co., Ltd., held 40.06% of the shares[10] Research and Development - Research and development expenses rose by 70.7% to RMB 2,414,037.41, up from RMB 1,414,191.19 in Q1 2018, indicating a focus on innovation[14] - Research and development expenses for Q1 2019 were ¥2,414,037.41, up 70.6% from ¥1,414,191.19 in Q1 2018[27] Other Financial Metrics - The weighted average return on equity decreased by 28.8 percentage points to 1.41%[6] - The company reported a non-recurring loss of CNY -478,153.08 for the period[9] - Financial expenses for Q1 2019 totaled ¥9,446,574.74, an increase of 94.5% from ¥4,869,123.86 in Q1 2018[27] - The company experienced a decrease in minority shareholders' profit from ¥5,662,960.04 in Q1 2018 to ¥3,425,387.41 in Q1 2019[28]